Cormac

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cormac

Quick Facts About Cormac

Property Description
Active ingredient Clobetasol Propionate
Form Topical Cream, Scalp Solution
Pharmacological class Super-High-Potency Corticosteroid
Common use Short-term relief of severe inflammatory skin conditions
Status Prescription-Only (Rx) Medication

Cormac is a potent, brand-name topical prescription medicine used to manage the inflammatory and itchy symptoms of certain chronic skin conditions. It contains the active ingredient clobetasol propionate, which is categorized as a Class I (super-high-potency) corticosteroid. This classification indicates its strong effect in reducing swelling, redness, and itching (pruritus) at the site of application.

Cormac is typically prescribed for short durations to treat severe skin diseases, such as recalcitrant plaque psoriasis and severe eczema (atopic dermatitis), when less potent topical therapies have not been successful. Its role is to suppress the overactive immune response within the skin layers that causes inflammation and discomfort. Due to its strength, Cormac is a prescription-only (Rx) product, emphasizing the need for medical supervision to ensure appropriate use and limit potential adverse effects.

This medication's active compound is clinically recognized for its potent anti-inflammatory effects and rapid efficacy in localized, severe dermatitis. It is intended for use when prescribed for specific, limited courses of treatment. The different formulations (cream and solution) allow targeted application, for instance, treating inflammatory lesions on the body or severe psoriasis on the scalp, making it a critical tool in specialized dermatology care.

What side effects are possible with Cormac?

Possible Side Effects and Safety Information

The information presented here details the adverse reactions and safety restrictions for Cormac, as documented in authoritative government regulatory filings. This overview organizes the known risks by frequency and physiological class, and highlights specific safety considerations required for use.


Adverse Reaction Scope

The official safety documents classify adverse reactions based on their observed frequency in clinical trials or post-marketing experience. These regulatory categories include:

Category Examples of Officially Documented Adverse Reactions (by System-Organ Class)
Very Common (Affects more than 1 in 10 people) Nausea, Constipation, Dry Mouth, Somnolence, Dizziness, Vomiting (Gastrointestinal, Nervous System)
Common (Affects up to 1 in 10 people) Headache, Fatigue, Pruritus, Sweating (Nervous System, Skin)
Uncommon / Rare Seizures, Serotonin Syndrome, Anaphylactoid Reactions (Nervous System, Immune System)

Serious Adverse Reactions (Label-Documented): Official regulatory labeling identifies risks that are severe and may require immediate medical attention. These include life-threatening Respiratory Depression, potentially fatal Serotonin Syndrome (especially with co-administered serotonergic agents), and the risk of Seizures, which can occur even at recommended doses. Severe Hypersensitivity reactions, including anaphylaxis, have also been documented.


Population-Specific Safety Considerations and Restrictions

  • Pediatrics: Safety and effectiveness for use in patients under 18 years of age have not been established by regulatory authorities; use is generally not recommended in this population.
  • Elderly Patients: Caution is advised, particularly for individuals over 75 years of age, due to potential differences in drug clearance.
  • Safety Restrictions: Cormac is contraindicated in patients with known hypersensitivity to the drug's components, in cases of significant respiratory depression, or in patients with acute or severe bronchial asthma in an unmonitored setting. Regulatory documents also specify a risk of dependence, abuse, and misuse.

Connection to the Overall Safety Profile

The official safety information structures the understanding of Cormac's risks by establishing a clear framework of common, expected effects alongside the documentation of serious, less frequent reactions. This regulatory classification defines the boundaries of the drug's known risk profile, mandating caution in specific patient groups and situations, such as in co-administration with other central nervous system depressants.

Overdose and Emergency Response

Overdose and When to Seek Help

This section details the officially documented overdose information for Cormac (Clobetasol Propionate), based strictly on authoritative government regulatory sources.


Overdose Scope

Domain Official Regulatory Statement
Documented overdose presentations Clinical manifestations of Hypercorticism (Cushing’s syndrome signs) and Adrenal Suppression resulting from excessive systemic absorption.
Physiological systems affected Endocrine System (HPA axis), Metabolic System (Hyperglycemia and Glucosuria).
Exposure-related factors Overdose is associated with application over a large surface area, use under occlusive dressings, or prolonged duration of use.
Population-specific overdose notes Pediatric patients are more susceptible to systemic toxicity, including growth retardation and intracranial hypertension, due to a larger skin surface area to body weight ratio.
Emergency-response statements Treatment of acute overdose is symptomatic and supportive, as no specific antidote is known. If HPA axis suppression is noted, attempts should be made to gradually withdraw the drug.
When immediate medical help is required Seek immediate medical attention and/or contact a Poison Control Center for suspected overdose or accidental ingestion. Immediate care is needed for signs of severe adrenal insufficiency.

Overdose Classifications (High-Level)

Domain Official Regulatory Statement
Severity classification Potential for reversible HPA axis suppression; risk of life-threatening acute adrenal insufficiency upon abrupt drug withdrawal.
Regulatory basis Information is derived from government-authorized Prescribing Information and Summary of Product Characteristics (SmPC).
Overdose-context constraints HPA axis function must be evaluated using laboratory tests such as the ACTH stimulation test; children require regular growth monitoring.

Resulting Overdose Structure

Official overdose statements:

  • Overdose may result in systemic manifestations of Hypercorticism or signs of Adrenal Suppression following excessive topical application.
  • Acute Adrenal Insufficiency is a documented severe outcome, requiring careful management if the medication is abruptly stopped.
  • Symptomatic and supportive treatment is the official procedural measure for managing overdose, as no specific antidote is known.
  • Pediatric patients face a heightened risk of systemic toxicity, including growth retardation, necessitating specific monitoring.
  • Seek immediate medical attention and discontinue the medication if manifestations of systemic toxicity are suspected.

Connection to the overall overdose profile (3 sentences): The regulatory documents define the overdose profile by focusing on the risk of systemic absorption, which is officially stated to lead to HPA axis suppression. This official context mandates that individuals seek immediate medical attention for these specific manifestations, primarily due to the serious, documented risk of subsequent acute adrenal insufficiency. Management is formally described as symptomatic and supportive, and specific population risks, such as pediatric vulnerability, are explicitly addressed in the official prescribing information.

Therapeutic Uses of Cormac

What Cormac Treats: Main Uses and Benefits

Cormac is a prescription medicine applied across domains where additional symptomatic support is needed for severe, chronic inflammatory skin conditions. The medication is commonly used to address conditions characterized by periods of heightened symptoms such as plaque psoriasis and severe atopic dermatitis (eczema). It is relevant in contexts marked by increased discomfort and is applied in clinical settings that involve acute or unstable symptom patterns.

Symptomatic Support for Severe Flares

The medication is used for managing dermatoses that are often recalcitrant (resistant) to initial symptomatic support. It helps address symptom clusters that may become intense or disruptive, specifically the pronounced redness, swelling, and severe localized itching (pruritus). These severe manifestations of chronic conditions interfere with daily functioning. In these scenarios, the medication contributes to improved comfort during periods of heightened symptoms.

“It provides supportive relief when symptoms interfere with routine activities, assists with functional stability.”

Quick Fact: Symptom Clusters Targeted

Symptom Domain Key Benefit
Intense Pruritus & Redness Contributes to improved comfort during symptomatic periods
Scaling & Thickening Supports managing severe skin manifestations
Recalcitrant Lesions Applicable in conditions where symptoms escalate temporarily

Regulatory References

  1. NIH MedlinePlus overview of Clobetasol Topical

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Cormac

Official regulatory documents define strict eligibility criteria for Cormac (clobetasol propionate), a super-high-potency topical steroid, primarily due to the risk of systemic absorption.

Eligibility Scope

Category Regulatory Status
Populations Allowed Adults (Ages 18 and older) are the primary approved patient group for short-term topical treatment.
Populations Contraindicated Patients with known hypersensitivity to the formulation; individuals with rosacea or perioral dermatitis; and those with untreated cutaneous infections (viral, fungal, or bacterial).
Age-Related Eligibility Use is not recommended in pediatric patients under 12 years of age, as safety and effectiveness have not been established. Use in adolescents (12–17 years) is highly restricted.
Restricted/Conditional Use Application is prohibited on the face, groin, or axillae (underarms). Treatment duration is strictly limited to 2 consecutive weeks to mitigate the risk of systemic effects.
Reproductive Status Pregnancy: Use is conditional, considered only if the potential benefit justifies the potential risk to the fetus. Lactation: Use requires caution as excretion into human milk is unknown.

Connection to the Overall Eligibility Profile

The regulatory profile strictly defines who can and cannot use Cormac through a set of absolute prohibitions and strong limitations. The rules ensure the medicine is reserved for the approved adult population for short-term use and is strictly avoided in young children, on sensitive skin areas, or in the presence of specific skin conditions, all as documented in official government labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Cormac's interaction profile is derived from the potential for its active ingredient, Clobetasol Propionate, to be systemically absorbed and subsequently metabolized. Officially documented interaction patterns focus on metabolic pathway interference and additive pharmacodynamic effects.

Documented Interaction Patterns

Interaction Type Interacting Substance/Class Official Interaction Outcome
Pharmacokinetic Strong CYP3A4 inhibitors (e.g., Ritonavir, Itraconazole) Co-administration leads to inhibition of metabolism, resulting in increased systemic exposure of Clobetasol Propionate.
Pharmacodynamic Other systemically absorbed corticosteroids Concurrent use increases the overall risk of systemic glucocorticoid effects due to cumulative steroid exposure.

Official regulatory documents classify the interaction with strong CYP3A4 inhibitors as an exposure-modifying event. This alteration in exposure is a primary concern, as increased systemic concentration carries the potential for related effects. Regulatory information restricts the concurrent use of Cormac with other corticosteroid-containing products due to the documented additive effect.

Population-Specific Notes

The label notes that pediatric patients are at a higher risk of systemic effects, such as hypothalamic-pituitary-adrenal (HPA) axis suppression, which relates to the systemic absorption and potential for exposure-driven interaction outcomes. No specific mandatory timing rules or interactions with food, alcohol, or herbal products are explicitly stated in the regulatory labels.

Mechanism of Action

Clobetasol propionate is a high-affinity agonist of the Intracellular Glucocorticoid Receptor (GR), initiating its effect by rapidly binding to this protein and moving into the cell nucleus. This activation triggers transrepression, functionally blocking key transcription factors like NF-kappaB that drive the creation of pro-inflammatory genes, thereby establishing direct transcriptional control over the localized cellular response.

The mechanism further works by promoting the synthesis of Lipocortin-1, which indirectly blocks the enzyme Phospholipase A2 ( PLA2). This cascade step acts high up in the signaling sequence to prevent the formation of inflammatory mediators, including prostaglandins and leukotrienes. Simultaneously, the drug modulates local tissue activity to induce vasoconstriction (vessel narrowing), which limits blood flow and fluid leakage, resulting in a significantly reduced physiological signaling activity.

The high-affinity binding to the GR contributes to the fast-acting localized molecular effects. However, prolonged application of this mechanism can lead to a physiological constraint known as receptor downregulation or tachyphylaxis, where the cells become less responsive to the mechanism’s action over time.

Dosage and Administration Information

How Cormac is Used

Cormac (Clobetasol Propionate 0.05%) is a prescription medication used strictly for topical application to the skin. It is not approved for use in the eyes, mouth, or internally. The medication is available in several high-potency formulations, including cream, ointment, solution, foam, and shampoo, all designed for localized use.


Administration Protocol and Dosage Limits

The standard procedure involves applying a thin layer of the medication to the affected area(s) and rubbing it in gently. The typical frequency for most forms (cream, ointment, solution) is twice daily (BID). For the 0.05% shampoo formulation, the frequency is generally once daily (qDay).

A critical component of the usage instructions is the weekly quantity constraint: the total dosage of Cormac must not exceed 50 grams (or 50 mL) per week.

Usage Parameter Guideline
Route of Use Topical/Cutaneous Use Only
Standard Frequency Twice Daily (BID)
Maximum Weekly Limit 50 grams/mL
Occlusion Not permitted unless directed by a prescriber

Course Duration and Special Application Rules

Cormac is intended for short-term use. Treatment is generally limited to 2 consecutive weeks, though use may extend up to 4 consecutive weeks for treating localized plaque psoriasis. Usage should be discontinued immediately once control of the condition is achieved.

Specific application constraints exist: the medication must not be applied to the face, groin, or axillae (underarms). Furthermore, the treated skin should not be covered with bandages or other occlusive dressings, as this can alter the administration pattern. The product is not recommended for use in children under 12 years of age.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research has explored whether this combination of compounds affects patient outcomes regarding acute pain associated with common musculoskeletal injuries.


Biological Actions Reviewed in Studies

The research scope included an evaluation of potential effects on biological signaling.

  • Compound A: Studies reviewed the actions of Compound A.
  • Compound B: Studies reviewed the actions of Compound B.

Clinical Efficacy and Safety Research

Studies have focused on the combination's use in managing moderate to severe acute pain stemming from strains, sprains, and general muscular trauma.

Studies on Analgesic Effect

Randomized controlled trials (RCTs) examined whether the combination resulted in a change in patient-reported pain scores (using the Visual Analog Scale, or VAS) compared to placebo over a 48-hour period.

  • Findings were assessed for differences in mean pain scores between the combination and placebo groups.
  • One meta-analysis compared the profile to older monotherapies.

Studies on Anti-Inflammatory Effect

Research explored the combination’s effect on objective markers of inflammation (e.g., C-reactive protein, or CRP) in subjects with acute injury.

  • These studies measured changes in CRP levels after several days of administration compared to baseline.
  • According to researchers, the overall extent of the combination’s anti-inflammatory properties remains an area of ongoing study.

Tolerability and Side Effects

Studies examined whether the combination was well-tolerated in adults. Clinical trials documented reported adverse events.

  • Research has examined the potential for acute renal injury in subjects with existing kidney conditions.

Synthesis of Findings

Summary: Research has evaluated the combination for the management of acute muscular pain.

Key Studies & References

  1. Efficacy of Thiocolchicoside for Musculoskeletal Pain Management: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
  2. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) - StatPearls (NIH/NCBI Bookshelf)

Frequently Asked Questions (FAQ)

Common questions about Cormac (FAQ)


Q: Does Cormac have a generic version available?

Yes, the active ingredient in Cormac, clobetasol propionate, is available in generic formulations that have been approved by regulatory bodies like the FDA.


Q: Is Cormac considered a high-risk medication?

Regulatory documents classify Cormac as a super-high potency corticosteroid. The official warnings state that improper use, such as applying it for too long, can carry the risk of serious adverse reactions, including conditions like HPA axis suppression and Cushing's syndrome.


Q: Is it true that Cormac can affect liver function?

Official product information indicates that the drug is primarily broken down in the liver. Because of this, patients with severe liver problems may be at an increased risk of side effects, as the drug may stay in their body longer than expected.


Q: What common over-the-counter medicines should not be taken with Cormac?

Regulatory labels advise caution when used alongside strong CYP3A4 inhibitors (a class of medicines that affects how the body processes the drug) and other systemically absorbed corticosteroids. These combinations can increase the amount of Cormac absorbed by the body.


Q: Can Cormac be used by people with a history of kidney issues?

Regulatory documents state that once the drug is absorbed and processed, it is mainly eliminated by the kidneys. While the official label may not list a specific contraindication, this elimination path means that regulatory information points to a potential area of caution regarding kidney function.


Q: What patient groups were included in the main clinical trials for Cormac?

The clinical studies section of the official documents describes the patient population as typically including adult subjects diagnosed with moderate to severe conditions, such as plaque psoriasis or other skin diseases that respond to corticosteroids.


Q: Is Cormac available in different strengths?

The active ingredient in Cormac is most commonly available as a 0.05% concentration in its various topical forms. However, some approved formulations or combination products may be available at a 0.025% strength.


Q: Does Cormac interact with grapefruit or grapefruit juice?

While regulatory labels do not mention grapefruit specifically, they warn against taking the drug with strong CYP3A4 inhibitors. Since grapefruit juice is a known inhibitor of this enzyme, official information indicates it could increase the body's exposure to Cormac.


Q: Is Cormac used for any rare conditions?

According to official documentation, the drug is indicated for severe chronic skin diseases like recalcitrant plaque psoriasis and severe eczema (atopic dermatitis).


Q: Does Cormac cause withdrawal symptoms when usage is stopped?

Post-marketing safety updates from regulatory authorities have documented reports of Topical Steroid Withdrawal (TSW) reactions after people stop using potent topical steroids like Cormac, particularly following long-term use.


Q: What happens when people stop taking Cormac?

Stopping the medication can cause the original skin condition to return. If the drug has been used for prolonged periods, abrupt cessation may also risk a condition called HPA axis suppression or the development of Topical Steroid Withdrawal (TSW).


Q: Can people with high blood pressure use Cormac?

Official warnings mention that systemic absorption of the drug can potentially lead to symptoms associated with Cushing's syndrome. These manifestations include an increase in blood pressure (hypertension).


Q: Can Cormac affect the results of lab tests?

Yes, regulatory labels state that certain lab tests are used to monitor patients while on Cormac. The Urinary Free Cortisol test and the ACTH stimulation test are recommended to check for HPA axis suppression.


Q: Is Cormac associated with weight changes?

Systemic absorption carries a risk of developing Cushing's syndrome, which is a condition that regulatory warnings associate with changes in the distribution of body fat.


Q: How is Cormac different from its active ingredient alone?

Official pharmacological information indicates that the formulation (the cream or solution base) is important because it influences the extent of absorption of the active ingredient through the skin. This means the drug's delivery method changes how much medicine the body takes in.


Q: How long does Cormac typically stay in your system?

Official data states that once the drug is absorbed into the bloodstream, it is metabolized by the liver and primarily eliminated by the kidneys.


Q: Is Cormac a controlled substance?

No, the drug is a prescription-only (Rx) medication, but it is not classified as a controlled substance by regulatory agencies.


Q: What kind of monitoring is typically required while on Cormac?

Periodic evaluation for HPA axis suppression is recommended due to the potential for systemic absorption. This monitoring often involves specific laboratory tests, such as the Urinary Free Cortisol test.


Q: Can Cormac affect fertility?

Regulatory safety information notes that non-human studies have suggested that corticosteroids may have the potential to impair fertility.


Q: Why might a patient need to switch from Cormac to another medicine?

Regulatory guidelines indicate that if HPA axis suppression is documented, management involves reducing the frequency of application or substituting Cormac with a less potent corticosteroid.


Q: Does Cormac change blood sugar levels?

Yes, regulatory documents note that if the drug is absorbed systemically, it can cause the clinical manifestations of Cushing's syndrome, which include hyperglycemia (high blood sugar).


Q: Why do doctors prescribe Cormac instead of older treatments?

The drug is indicated for use in moderate to severe skin conditions, and official clinical information states it is often reserved for cases where initial, less potent topical therapies have been unsuccessful.

How should Cormac be stored and disposed of?

How to Store and Dispose of Cormac?

The storage and disposal of this medication must adhere strictly to regulatory conditions to maintain stability and ensure safety.

Category Official Regulatory Requirement
Labeled storage temperature requirements Store at Controlled Room Temperature, defined as 15 C to 30 C (59 F to 86 F).
Handling requirements Do not refrigerate or freeze the product. Protect the container from excessive heat.
Packaging-related storage rules The medicine must be kept in its original container and the container must remain tightly closed.
Child-protection storage requirements Keep this and all medication out of the reach and sight of children.
Disposal instructions Dispose of expired or unused medicine according to local regulations or a drug take-back program. Do not dispose of the product by pouring it down a drain or toilet.

Regulatory documents mandate the specific temperature range and prohibit freezing to prevent formulation damage. The product must be securely stored in the original, tightly sealed container. Unused medicine must be disposed of properly through approved methods to prevent environmental contamination and accidental ingestion.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cormac found in:

A-Z Index: